Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham
June 16, 2025 • CAR-T Content Hub
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and frequent visits. Now, immunotherapy is changing the game. By reprogramming a patient’s own T cells to target BCMA, a protein found on myeloma cells, CAR T-cell therapy offers deeper, longer remissions. This one-time treatment is helping patients live longer with fewer side effects, giving families back their time and hope. Learn how this cutting-edge approach is reshaping multiple myeloma care.
